ADMET Prediction and Molecular Simulation of Prosopis juliflora Against Lung Cancer Protein (ATK1)

Author:

S. Arun Pandiyan1,Gokul V.1,Madhumitha L.1,Pazhamalai Vivek1,S. Ivo Romauld1,Meenambiga S. S.1ORCID

Affiliation:

1. Vels Institute of Science, Technology, and Advanced Studies, India

Abstract

With 85% of cases being non-small-cell lung cancer (NSCLC), it is the most prevalent form of the disease. NSCLC normally develops and spreads more slowly than its counterpart, small-cell lung cancer (SCLC), which may result in a worse outcome. Adenocarcinoma, squamous cell carcinoma, and giant cell carcinoma are only a few of the subtypes of NSCLC. Each has distinct traits and approaches to treatment. Smoking continues to be a substantial risk factor for NSCLC, although it can also afflict non-smokers. This work involves development of potential anti-cancer drug from the bioactive compounds of Prosopis juliflora, an invasive shrub which is found in all over the state of Tamil Nadu. The bioactive compounds of Prosopis juliflora were screened for ADMET properties and docked against the RAC-alpha serine/threonine-protein kinase (PDB: 3o96). Then, the compound Phenol, 3,5-bis(1,1-dimethylethyl)- which has the least binding energy of -6.95 kcal/mol was used to model the firmness and dynamics of the free protein 10 picoseconds.

Publisher

IGI Global

Reference17 articles.

1. Worldwide Overview of the Current Status of Lung Cancer Diagnosis and Treatment

2. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules

3. Treatment of lung cancer.;S. M.Gadgeel;Radiologia Clinica,2012

4. GhoshJ.LawlessM. S.WaldmanM.GombarV.FraczkiewiczR. (2016). Modeling admet. In Silico Methods for Predicting Drug Toxicity, 63-83.

5. Roles of AKT1 and AKT2 in non-small cell lung cancer cell survival, growth, and migration

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3